Milestone Resources Group Ltd Sells 994 Shares of Zoetis Inc. (NYSE:ZTS)

Milestone Resources Group Ltd cut its position in Zoetis Inc. (NYSE:ZTS) by 0.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 608,819 shares of the company’s stock after selling 994 shares during the quarter. Zoetis comprises about 3.3% of Milestone Resources Group Ltd’s holdings, making the stock its 15th largest position. Milestone Resources Group Ltd owned about 0.13% of Zoetis worth $99,195,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in ZTS. GM Advisory Group LLC grew its stake in Zoetis by 13.2% in the 4th quarter. GM Advisory Group LLC now owns 2,149 shares of the company’s stock valued at $350,000 after buying an additional 250 shares in the last quarter. Vinva Investment Management Ltd boosted its holdings in shares of Zoetis by 9.6% in the fourth quarter. Vinva Investment Management Ltd now owns 21,323 shares of the company’s stock worth $3,459,000 after acquiring an additional 1,867 shares during the period. OVERSEA CHINESE BANKING Corp Ltd grew its position in shares of Zoetis by 3.4% in the fourth quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 156,335 shares of the company’s stock valued at $25,472,000 after purchasing an additional 5,181 shares in the last quarter. Xponance Inc. grew its position in shares of Zoetis by 2.7% in the fourth quarter. Xponance Inc. now owns 106,939 shares of the company’s stock valued at $17,424,000 after purchasing an additional 2,814 shares in the last quarter. Finally, Generali Asset Management SPA SGR purchased a new stake in Zoetis during the 4th quarter worth about $10,457,000. Institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on ZTS shares. Piper Sandler lifted their target price on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. Morgan Stanley reduced their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. StockNews.com upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Stifel Nicolaus cut their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Finally, Leerink Partners initiated coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $215.90.

Insider Activity

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now directly owns 11,245 shares of the company’s stock, valued at $1,868,244.30. The trade was a 9.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the sale, the executive vice president now owns 15,781 shares of the company’s stock, valued at $2,682,770. The trade was a 2.02 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,862 shares of company stock valued at $312,254. 0.16% of the stock is currently owned by insiders.

Zoetis Trading Down 0.5 %

Shares of ZTS stock opened at $164.28 on Wednesday. The business has a 50-day moving average price of $166.83 and a two-hundred day moving average price of $175.84. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.33. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The firm has a market cap of $73.56 billion, a P/E ratio of 30.03, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.22%. Zoetis’s payout ratio is 36.56%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.